Drug Patents Expiring in 2037

1. Adlarity patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11679086 CORIUM Systems comprising a composite backing and methods for long term transdermal administration
May, 2037

(12 years from now)

US11103463 CORIUM Methods for treating alzheimer's disease with donepezil transdermal system
Jul, 2037

(12 years from now)

US10300025 CORIUM Donepezil transdermal delivery system
Jul, 2037

(12 years from now)

US10016372 CORIUM Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
Jul, 2037

(12 years from now)

US10307379 CORIUM Donepezil transdermal delivery system
Jul, 2037

(12 years from now)

US9993466 CORIUM Donepezil transdermal delivery system
Jul, 2037

(12 years from now)

US11648214 CORIUM Systems and methods for long term transdermal administration
Sep, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 11, 2025

Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient

Market Authorisation Date: 11 March, 2022

Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type

Dosage: SYSTEM

More Information on Dosage

ADLARITY family patents

Family Patents

2. Airduo Digihaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10569034

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Akeega patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11986468 JANSSEN BIOTECH Methods of treating prostate cancer
Jul, 2037

(12 years from now)

US11986469 JANSSEN BIOTECH Methods of treating prostate cancer
Jul, 2037

(12 years from now)

US11207311 JANSSEN BIOTECH Method of treating prostate cancer
Jul, 2037

(12 years from now)

US11992486 JANSSEN BIOTECH Methods of treating prostate cancer
Jul, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET

More Information on Dosage

AKEEGA family patents

Family Patents

4. Akynzeo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624911 HELSINN HLTHCARE Physiologically balanced injectable formulations of fosnetupitant
Jun, 2037

(12 years from now)

US11529362 HELSINN HLTHCARE Physiologically balanced injectable formulations of fosnetupitant
Jun, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 19 April, 2022

Market Authorisation Date: 19 April, 2018

Treatment: NA

Dosage: SOLUTION; POWDER

How can I launch a generic of AKYNZEO before it's drug patent expiration?
More Information on Dosage

AKYNZEO family patents

Family Patents

5. Amzeeq patent expiration

Can you believe AMZEEQ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398641 JOURNEY Compositions and methods for treating rosacea and acne
Sep, 2037

(12 years from now)

US10849847 JOURNEY Compositions and methods for treating rosacea and acne
Sep, 2037

(12 years from now)




Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 October, 2019

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM

How can I launch a generic of AMZEEQ before it's drug patent expiration?
More Information on Dosage

AMZEEQ family patents

Family Patents

6. Armonair Digihaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10569034

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

7. Atorvaliq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11369567 CMP DEV LLC Aqueous suspension suitable for oral administration
Jun, 2037

(12 years from now)

US11654106 CMP DEV LLC Aqueous suspension suitable for oral administration
Jun, 2037

(12 years from now)

US11925704 CMP DEV LLC Aqueous suspension suitable for oral administration
Jun, 2037

(12 years from now)




Drugs and Companies using ATORVASTATIN CALCIUM ingredient

Market Authorisation Date: 01 February, 2023

Treatment: As an adjunct to other low-density lipoprotein cholesterol (ldl-c) lowering therapies, or alone if such treatments are unavailable, to reduce ldl-c in adults and pediatric patients aged 10 years and o...

Dosage: SUSPENSION

More Information on Dosage

ATORVALIQ family patents

Family Patents

8. Auvi-q patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842938 KALEO INC Medicament delivery device and methods for delivering drugs to infants and children
Dec, 2037

(13 years from now)

US10688244 KALEO INC Medicament delivery device and methods for delivering drugs to infants and children
Dec, 2037

(13 years from now)

US11771830 KALEO INC Medicament delivery device and methods for delivering drugs to infants and children
Dec, 2037

(13 years from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 17 November, 2017

Treatment: Method of treating an allergic reaction using an auto-injector

Dosage: SOLUTION

More Information on Dosage

AUVI-Q family patents

Family Patents

9. Azstarys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10584112 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10584113 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

US10759778 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

US10858341 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

US10954213 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 07, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: 07 May, 2025

Market Authorisation Date: 07 May, 2021

Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate

Dosage: CAPSULE

More Information on Dosage

AZSTARYS family patents

Family Patents

10. Bludigo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11499050 PROVEPHARM SAS Process for the preparation of indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(13 years from now)

US10927258 PROVEPHARM SAS Process for the preparation of Indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 08, 2027

Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient

NCE-1 date: 08 July, 2026

Market Authorisation Date: 08 July, 2022

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

BLUDIGO family patents

Family Patents

11. Brukinsa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11851437 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

US10927117 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11970500 BEIGENE Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

US11591340 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

US11884674 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-871) Aug 31, 2024
New Indication(I-874) Sep 14, 2024
New Chemical Entity Exclusivity(NCE) Nov 14, 2024
New Indication(I-817) Jan 19, 2026
Orphan Drug Exclusivity(ODE-276) Nov 14, 2026
New Indication(I-936) Mar 07, 2027
Orphan Drug Exclusivity(ODE-371) Aug 31, 2028
Orphan Drug Exclusivity(ODE-370) Sep 14, 2028
Orphan Drug Exclusivity(ODE-274) Jan 19, 2030
Orphan Drug Exclusivity(ODE-467) Mar 07, 2031

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: 15 November, 2023

Market Authorisation Date: 14 November, 2019

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) who have received at least one p...

Dosage: CAPSULE

More Information on Dosage

BRUKINSA family patents

Family Patents

12. Cabometyx patent expiration

Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141413 EXELIXIS INC Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
Apr, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
New Product(NP) Apr 25, 2019
New Indication(I-760) Dec 19, 2020
New Indication(I-792) Jan 14, 2022
New Indication(I-854) Jan 22, 2024
New Indication(I-873) Sep 17, 2024
Orphan Drug Exclusivity(ODE-227) Jan 14, 2026
Orphan Drug Exclusivity(ODE-375) Sep 17, 2028

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy

Dosage: TABLET

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

13. Calcium Gluconate In Sodium Chloride patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10342813 HQ SPCLT PHARMA Calcium gluconate solutions in flexible containers
Jul, 2037

(12 years from now)

US10130646 HQ SPCLT PHARMA Calcium gluconate solutions in flexible containers
Jul, 2037

(12 years from now)




Drugs and Companies using CALCIUM GLUCONATE ingredient

Market Authorisation Date: 29 October, 2018

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

CALCIUM GLUCONATE IN SODIUM CHLORIDE family patents

Family Patents

14. Cequa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10918694 SUN PHARM Topical cyclosporine-containing formulations and uses thereof
Feb, 2037

(12 years from now)

US11951153 SUN PHARM Topical cyclosporine-containing formulations and uses thereof
Feb, 2037

(12 years from now)




Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 14 August, 2018

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION

More Information on Dosage

CEQUA family patents

Family Patents

15. Definity patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11857646 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US11266750 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US11529431 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US10583208 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US11925695 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US9789210 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US10588988 LANTHEUS MEDCL Methods and devices for preparation of ultrasound contrast agents
May, 2037

(12 years from now)




Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE

More Information on Dosage

DEFINITY family patents

Family Patents

16. Definity Rt patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11857646 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US10583208 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US9789210 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US11529431 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US11266750 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US11925695 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US10588988 LANTHEUS MEDCL Methods and devices for preparation of ultrasound contrast agents
May, 2037

(12 years from now)




Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE

More Information on Dosage

DEFINITY RT family patents

Family Patents

17. Dextenza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458041 OCULAR THERAPEUTIX Punctal plug and bioadhesives
Nov, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 30, 2021
New Indication(I-800) Jun 20, 2022
New Indication(I-876) Oct 07, 2024

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: Treatment of ocular inflammation and pain following ophthalmic surgery

Dosage: INSERT

More Information on Dosage

DEXTENZA family patents

Family Patents

18. Drizalma Sprinkle patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11202772 SUN PHARM Duloxetine sprinkles
Apr, 2037

(12 years from now)

US10413525 SUN PHARM Duloxetine sprinkles
Apr, 2037

(12 years from now)

US9839626 SUN PHARM Duloxetine sprinkles
Apr, 2037

(12 years from now)

US10959982 SUN PHARM Duloxetine sprinkles
Apr, 2037

(12 years from now)




Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 July, 2019

Treatment: NA

Dosage: CAPSULE, DELAYED REL PELLETS

More Information on Dosage

DRIZALMA SPRINKLE family patents

Family Patents

19. Edurant Ped patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065198 JANSSEN PRODS Dispersible compositions
Oct, 2037

(12 years from now)




Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 March, 2024

Treatment: NA

Dosage: TABLET, FOR SUSPENSION

More Information on Dosage

EDURANT PED family patents

Family Patents

20. Entresto Sprinkle patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722471 NOVARTIS Galenic formulations of organic compounds
Feb, 2037

(12 years from now)




Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 12 April, 2024

Treatment: Treatment of heart failure with oral pellets

Dosage: CAPSULE, PELLETS

More Information on Dosage

ENTRESTO SPRINKLE family patents

Family Patents

21. Esbriet patent expiration

ESBRIET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188637 GENENTECH INC Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
Mar, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE) Oct 15, 2021
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021

Drugs and Companies using PIRFENIDONE ingredient

NCE-1 date: 15 October, 2018

Market Authorisation Date: 11 January, 2017

Treatment: NA

Dosage: TABLET

How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage

ESBRIET family patents

Family Patents

22. Evekeo Odt patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11896562 AZURITY Oral amphetamine composition
Mar, 2037

(12 years from now)

US11160772 AZURITY Oral amphetamine composition
Mar, 2037

(12 years from now)

US10441554 AZURITY Oral amphetamine composition
Mar, 2037

(12 years from now)




Drugs and Companies using AMPHETAMINE SULFATE ingredient

Market Authorisation Date: 16 April, 2021

Treatment: Treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients

Dosage: TABLET, ORALLY DISINTEGRATING

More Information on Dosage

EVEKEO ODT family patents

Family Patents

23. Fintepla patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10947183

(Pediatric)

UCB INC Fenfluramine compositions and methods of preparing the same
Jun, 2037

(12 years from now)

US11759440 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(12 years from now)

US10603290 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(12 years from now)

US11040018 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(12 years from now)

US11406606 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(12 years from now)

US11786487 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 25, 2023
New Indication(I-887) Mar 25, 2025
Orphan Drug Exclusivity(ODE-312) Jun 25, 2027
Orphan Drug Exclusivity(ODE-393) Mar 25, 2029
Pediatric Exclusivity(PED) Sep 25, 2029

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Method of reducing or ameliorating seizures in a patient by administering a liquid formulation of fenfluramine with stiripentol thereby modulating down the formation of norfenfluramine and resulting i...

Dosage: SOLUTION

How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage

FINTEPLA family patents

Family Patents

24. Firdapse patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10626088 CATALYST PHARMS Determining degradation of 3,4-diaminopyridine
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 28, 2023
New Patient Population(NPP) Sep 29, 2025
Orphan Drug Exclusivity(ODE-223) Nov 28, 2025

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: 28 November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: NA

Dosage: TABLET

How can I launch a generic of FIRDAPSE before it's drug patent expiration?
More Information on Dosage

FIRDAPSE family patents

Family Patents

25. Fleqsuvy patent expiration

Can you believe FLEQSUVY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446246 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(12 years from now)

US11324696 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(12 years from now)




Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 04 February, 2022

Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis

Dosage: SUSPENSION

How can I launch a generic of FLEQSUVY before it's drug patent expiration?
More Information on Dosage

FLEQSUVY family patents

Family Patents

26. Fluorescein Sodium And Benoxinate Hydrochloride patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632197 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions
Nov, 2037

(12 years from now)

US10293047 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions
Nov, 2037

(12 years from now)

US10842872 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions
Nov, 2037

(12 years from now)




Drugs and Companies using BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM ingredient

Market Authorisation Date: 09 March, 2020

Treatment: Ocular examination, intraocular pressure measurement, or removal of foreign bodies or sutures, in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic ane...

Dosage: SOLUTION/DROPS

More Information on Dosage

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE family patents

Family Patents

27. Galafold patent expiration

GALAFOLD's oppositions filed in EPO
Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234972 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(12 years from now)

US10076514 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 10, 2023
Orphan Drug Exclusivity(ODE-205) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE

How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage

GALAFOLD family patents

Family Patents

28. Giapreza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11219662 LA JOLLA PHARMA Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
Jan, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 21 December, 2021

Market Authorisation Date: 23 December, 2021

Treatment: Treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor

Dosage: SOLUTION

How can I launch a generic of GIAPREZA before it's drug patent expiration?
More Information on Dosage

GIAPREZA family patents

Family Patents

29. Gloperba patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226423 SCILEX PHARMS Colchicine drug-to-drug interactions
Dec, 2037

(13 years from now)




Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 30 January, 2019

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of GLOPERBA before it's drug patent expiration?
More Information on Dosage

GLOPERBA family patents

Family Patents

30. Goprelto patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10987347 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10413505 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US9867815 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10894012 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10149843 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US11040032 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10016407 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10420760 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10857095 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10231961 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10933060 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10973811 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2022

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 14 December, 2021

Market Authorisation Date: 14 December, 2017

Treatment: Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; Method of administering a local anesthetic to the mucous membranes; Method of administering a lo...

Dosage: SOLUTION

More Information on Dosage

GOPRELTO family patents

Family Patents

31. Hemady patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11304961 DEXCEL Compositions comprising dexamethasone
Dec, 2037

(13 years from now)

US10537585 DEXCEL Compositions comprising dexamethasone
Dec, 2037

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-271) Oct 03, 2026

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 03 October, 2019

Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product

Dosage: TABLET

More Information on Dosage

HEMADY family patents

Family Patents

32. Igalmi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11839604 BIOXCEL Use of sublingual dexmedetomidine for the treatment of agitation
Dec, 2037

(13 years from now)

US11786508 BIOXCEL Use of sublingual dexmedetomidine for the treatment of agitation
Dec, 2037

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 05, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with bipolar i or ii disorder by sublingual or buccal administration; Acute treatment of agitation associated with schizophrenia by sublingual or buccal adminis...

Dosage: FILM

More Information on Dosage

IGALMI family patents

Family Patents

33. Ingrezza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912771 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US10857148 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US10993941 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US10952997 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US10874648 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US10857137 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US11439629 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US11040029 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 11, 2022
New Indication(I-925) Aug 18, 2026
Orphan Drug Exclusivity(ODE-440) Aug 18, 2030

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: 11 April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: CAPSULE

How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage

INGREZZA family patents

Family Patents

34. Ingrezza Sprinkle patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10993941 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US10912771 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US10952997 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US11040029 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US11439629 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US10857137 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US10874648 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)

US10857148 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-925) Aug 18, 2026

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Market Authorisation Date: 30 April, 2024

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: CAPSULE

More Information on Dosage

INGREZZA SPRINKLE family patents

Family Patents

35. Inlyta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869924 PF PRISM CV PD-L1 antagonist combination treatments
Jan, 2037

(12 years from now)

US10869924

(Pediatric)

PF PRISM CV PD-L1 antagonist combination treatments
Jul, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 27, 2017

Drugs and Companies using AXITINIB ingredient

NCE-1 date: 28 January, 2016

Market Authorisation Date: 27 January, 2012

Treatment: Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET

How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage

INLYTA family patents

Family Patents

36. Iqirvo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11850223 IPSEN Methods of treatment of cholestatic diseases
Mar, 2037

(12 years from now)

US11331292 IPSEN Methods of treatment of cholestatic diseases
Mar, 2037

(12 years from now)

US11857523 IPSEN Methods of treatment of cholestatic diseases
Mar, 2037

(12 years from now)

US11185519 IPSEN Methods of treatment of cholestatic diseases
Mar, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 10, 2029
Orphan Drug Exclusivity(ODE-486) Jun 10, 2031

Drugs and Companies using ELAFIBRANOR ingredient

NCE-1 date: 10 June, 2028

Market Authorisation Date: 10 June, 2024

Treatment: Treatment of primary biliary cholangitis (pbc); Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response to udca, or...

Dosage: TABLET

More Information on Dosage

IQIRVO family patents

Family Patents

37. Katerzia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10894039 AZURITY Amlodipine formulations
Oct, 2037

(12 years from now)

US12053461 AZURITY Amlodipine formulations
Oct, 2037

(12 years from now)

US11364230 AZURITY Amlodipine formulations
Oct, 2037

(12 years from now)

US11701326 AZURITY Amlodipine formulations
Oct, 2037

(12 years from now)

US11918685 AZURITY Amlodipine formulations
Oct, 2037

(12 years from now)

US10959991 AZURITY Amlodipine formulations
Oct, 2037

(12 years from now)

US11471409 AZURITY Amlodipine formulations
Oct, 2037

(12 years from now)

US10952998 AZURITY Amlodipine formulations
Oct, 2037

(12 years from now)

US11484498 AZURITY Amlodipine formulations
Oct, 2037

(12 years from now)

US10695329 AZURITY Amlodipine formulations
Oct, 2037

(12 years from now)




Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: Method of treating hypertension; A method of treating hypertension; Angina

Dosage: SUSPENSION

How can I launch a generic of KATERZIA before it's drug patent expiration?
More Information on Dosage

KATERZIA family patents

Family Patents

38. Korlym patent expiration

KORLYM IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10151763 CORCEPT THERAP Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome
Jan, 2037

(12 years from now)

US10195214 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Jun, 2037

(12 years from now)

US10842800 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Jun, 2037

(12 years from now)

US12097210 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Jun, 2037

(12 years from now)

US11969435 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Jun, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 17, 2015
Orphan Drug Exclusivity(ODE) Feb 17, 2019
Orphan Drug Exclusivity(ODE-22) Feb 17, 2019

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET

How can I launch a generic of KORLYM before it's drug patent expiration?
More Information on Dosage

KORLYM family patents

Family Patents

39. Krazati patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10689377 BRISTOL KRas G12C inhibitors
May, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 12, 2027
Orphan Drug Exclusivity(ODE-352) Dec 12, 2029

Drugs and Companies using ADAGRASIB ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 12 December, 2022

Treatment: Treatment, in combination with cetuximab, of adult patients with kras g12c-muted locally advanced or metastatic colorectal cancer, per fda approved test, where prior treatment with fluoropyrimidine-, ...

Dosage: TABLET

More Information on Dosage

KRAZATI family patents

Family Patents

40. Leqselvi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12076323 SUN PHARM INDS INC Treatment of hair loss disorders with deuterated JAK inhibitors
May, 2037

(12 years from now)

US10561659 SUN PHARM INDS INC Treatment of hair loss disorders with deuterated JAK inhibitors
May, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 25, 2029

Drugs and Companies using DEURUXOLITINIB PHOSPHATE ingredient

NCE-1 date: 25 July, 2028

Market Authorisation Date: 25 July, 2024

Treatment: Treatment of adult patients with alopecia areata

Dosage: TABLET

More Information on Dosage

LEQSELVI family patents

Family Patents

41. Lexette patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857159

(Pediatric)

MAYNE PHARMA Halobetasol foam composition and method of use thereof
May, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) May 24, 2021
New Patient Population(NPP) Aug 18, 2024

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 24 May, 2018

Treatment: NA

Dosage: AEROSOL, FOAM

How can I launch a generic of LEXETTE before it's drug patent expiration?
More Information on Dosage

LEXETTE family patents

Family Patents

42. Lonsurf patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456399 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(12 years from now)

US10960004 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 22, 2020
New Indication(I-794) Feb 22, 2022
Orphan Drug Exclusivity(ODE-229) Feb 22, 2026

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

NCE-1 date: 23 September, 2019

Market Authorisation Date: 22 September, 2015

Treatment: Treatment of metastatic colorectal cancer alone or with bevacizumab in severely renally impaired patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan therapy, an anti-vegf b...

Dosage: TABLET

How can I launch a generic of LONSURF before it's drug patent expiration?
More Information on Dosage

LONSURF family patents

Family Patents

43. Lumryz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10973795 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US11602513 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US11602512 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US11400065 AVADEL CNS Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
Jul, 2037

(12 years from now)

US11986451 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US10952986 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US11826335 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US12097176 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US11896572 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US11839597 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US12109186 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US11766418 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US11065224 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US10272062 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US12115143 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US12115144 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US12115142 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US11504347 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US12097175 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US12115145 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US11052061 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US10736866 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)

US11000498 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 01, 2026
Orphan Drug Exclusivity(ODE-431) May 01, 2030
Orphan Drug Exclusivity(ODE-494) Oct 16, 2031

Drugs and Companies using SODIUM OXYBATE ingredient

Market Authorisation Date: 01 May, 2023

Treatment: Treatment of narcolepsy-related cataplexy or excessive daytime sleepiness using a once-daily pharmaceutical formulation comprising an oxybate; Treatment of narcolepsy-related cataplexy or excessive da...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

LUMRYZ family patents

Family Patents

44. Lupkynis patent expiration

LUPKYNIS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11622991 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(13 years from now)

US10286036 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 22, 2026

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 22 January, 2025

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE

More Information on Dosage

LUPKYNIS family patents

Family Patents

45. Miebo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10507132 BAUSCH AND LOMB INC Topical administration method
Jun, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 18, 2028

Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient

NCE-1 date: 19 May, 2027

Market Authorisation Date: 18 May, 2023

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS

More Information on Dosage

MIEBO family patents

Family Patents

46. Myfembree patent expiration

MYFEMBREE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033551 SUMITOMO PHARMA Methods of treating uterine fibroids
Sep, 2037

(12 years from now)

US11957684 SUMITOMO PHARMA Treatment of heavy menstrual bleeding associated with uterine fibroids
Sep, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 26, 2024
New Indication(I-898) Aug 05, 2025
New Chemical Entity Exclusivity(NCE) Dec 18, 2025
M(M-289) Jan 27, 2026

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET

More Information on Dosage

MYFEMBREE family patents

Family Patents

47. Numbrino patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933060 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US9867815 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10973811 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10894012 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10420760 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10857095 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10413505 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10149843 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10016407 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10231961 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US11040032 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2022
New Product(NP) Jan 10, 2023

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 14 December, 2021

Market Authorisation Date: 10 January, 2020

Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; A method for treating a subj...

Dosage: SOLUTION

More Information on Dosage

NUMBRINO family patents

Family Patents

48. Nuplazid patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10517860 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(12 years from now)

US10953000 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 29, 2021

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

NCE-1 date: 29 April, 2020

Market Authorisation Date: 28 June, 2018

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis

Dosage: TABLET

How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage

NUPLAZID family patents

Family Patents

49. Nuzyra patent expiration

Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10111890 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and uses thereof
Aug, 2037

(12 years from now)

US10835542 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(12 years from now)

US10383884 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 02, 2023
Generating Antibiotic Incentives Now(GAIN) Oct 02, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 03 October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: Treatment of subjects having bacterial skin or skin structure infection; Treatment of community acquired bacterial pneumonia

Dosage: TABLET; POWDER

More Information on Dosage

NUZYRA family patents

Family Patents

50. Opfolda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857212 AMICUS THERAP US Augmented acid alpha-glucosidase for the treatment of Pompe disease
Aug, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 28, 2026

Drugs and Companies using MIGLUSTAT ingredient

Market Authorisation Date: 28 September, 2023

Treatment: The treatment of pompe patients

Dosage: CAPSULE

More Information on Dosage

OPFOLDA family patents

Family Patents

51. Orgovyx patent expiration

ORGOVYX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786501 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(12 years from now)

US10449191 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(12 years from now)

US12097198 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(12 years from now)

US11583526 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer

Dosage: TABLET

More Information on Dosage

ORGOVYX family patents

Family Patents

52. Otiprio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040004 ALK ABELLO Otic gel formulations for treating otitis externa
Nov, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 10, 2018
New Indication(I-770) Mar 02, 2021

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus

Dosage: INJECTABLE, SUSPENSION

More Information on Dosage

OTIPRIO family patents

Family Patents

53. Oxbryta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10493035 GLOBAL BLOOD THERAPS Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Oct, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 25, 2024
Orphan Drug Exclusivity(ODE-281) Nov 25, 2026
Orphan Drug Exclusivity(ODE-394) Dec 17, 2028

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 26 November, 2023

Market Authorisation Date: 14 October, 2022

Treatment: NA

Dosage: TABLET

More Information on Dosage

OXBRYTA family patents

Family Patents

54. Pizensy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10806743 BRAINTREE LABS Method of administering lactitol to reduce plasma concentration of lactitol
May, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 12, 2025

Drugs and Companies using LACTITOL ingredient

NCE-1 date: 13 February, 2024

Market Authorisation Date: 12 February, 2020

Treatment: Method of treating chronic idiopathic constipation in adult patients.

Dosage: FOR SOLUTION

More Information on Dosage

PIZENSY family patents

Family Patents

55. Procysbi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905662

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)

US10328037

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)

US10143665

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)

US10548859

(Pediatric)

HORIZON Methods for storing Cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Apr 30, 2016
New Patient Population(NPP) Aug 14, 2018
Orphan Drug Exclusivity(ODE-45) Apr 30, 2020
M(M-216) Dec 22, 2020
Orphan Drug Exclusivity(ODE) Aug 14, 2022
Orphan Drug Exclusivity(ODE-97) Aug 14, 2022
ODE*(ODE*) Dec 22, 2024
Orphan Drug Exclusivity(ODE-162) Dec 22, 2024
Pediatric Exclusivity(PED) Jun 22, 2025

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 30 April, 2013

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE; GRANULE, DELAYED RELEASE

How can I launch a generic of PROCYSBI before it's drug patent expiration?
More Information on Dosage

PROCYSBI family patents

Family Patents

56. Pylarify patent expiration

Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11851407 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL
Jun, 2037

(12 years from now)

US10947197 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL
Jun, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 26, 2026

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

NCE-1 date: 26 May, 2025

Market Authorisation Date: 26 May, 2021

Treatment: Method of positron emission tomography (pet) in men with prostate cancer

Dosage: SOLUTION

More Information on Dosage

PYLARIFY family patents

Family Patents

57. Qlosi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10639297 ORASIS PHARMS Ophthalmic pharmaceutical compositions and uses relating thereto
Aug, 2037

(12 years from now)

US11974986 ORASIS PHARMS Ophthalmic pharmaceutical compositions and uses relating thereto
Aug, 2037

(12 years from now)

US11129812 ORASIS PHARMS Ophthalmic pharmaceutical compositions and uses relating thereto
Aug, 2037

(12 years from now)

US9867810 ORASIS PHARMS Ophthalmic pharmaceutical compositions and uses relating thereto
Aug, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 17, 2026

Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 October, 2023

Treatment: Treatment of presbyopia

Dosage: SOLUTION

More Information on Dosage

QLOSI family patents

Family Patents

58. Retevmo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10112942 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10137124 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Oct, 2037

(12 years from now)

US10172851 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 08, 2025
Orphan Drug Exclusivity(ODE-301) May 08, 2027
Orphan Drug Exclusivity(ODE-302) May 08, 2027
Orphan Drug Exclusivity(ODE-303) May 08, 2027
New Patient Population(NPP) May 29, 2027
Orphan Drug Exclusivity(ODE-409) Sep 21, 2029
Orphan Drug Exclusivity(ODE-412) Sep 21, 2029
Orphan Drug Exclusivity(ODE-484) May 29, 2031
Orphan Drug Exclusivity(ODE-485) May 29, 2031
Orphan Drug Exclusivity(ODE-487) May 29, 2031

Drugs and Companies using SELPERCATINIB ingredient

NCE-1 date: 08 May, 2024

Market Authorisation Date: 08 May, 2020

Treatment: Treatment of adult or pediatric patients 2 years of age or older with advanced or metastatic thyroid cancer with a ret gene fusion, as detected by an fda-approved test, who require systemic therapy an...

Dosage: CAPSULE; TABLET

More Information on Dosage

RETEVMO family patents

Family Patents

59. Reyvow patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2025

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

NCE-1 date: 01 February, 2024

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine

Dosage: TABLET

More Information on Dosage

REYVOW family patents

Family Patents

60. Rezzayo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11712459 MUNDIPHARMA Dosing regimens for treatment of fungal infections
Mar, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 22, 2028
Orphan Drug Exclusivity(ODE-426) Mar 22, 2030
Generating Antibiotic Incentives Now(GAIN) Mar 22, 2033

Drugs and Companies using REZAFUNGIN ACETATE ingredient

NCE-1 date: 22 March, 2032

Market Authorisation Date: 22 March, 2023

Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration

Dosage: POWDER

More Information on Dosage

REZZAYO family patents

Family Patents

61. Rozlytrek patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 15, 2024
Orphan Drug Exclusivity(ODE-265) Aug 15, 2026
Orphan Drug Exclusivity(ODE-313) Aug 15, 2026
New Product(NP) Oct 20, 2026
New Patient Population(NPP) Oct 20, 2026
Orphan Drug Exclusivity(ODE-448) Oct 20, 2030

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: 16 August, 2023

Market Authorisation Date: 15 August, 2019

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of colorectal cancer that has a neurotrophic tyrosine receptor kinase(ntrk) gene fusion

Dosage: CAPSULE

More Information on Dosage

ROZLYTREK family patents

Family Patents

62. Saxenda patent expiration

SAXENDA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968659 NOVO Liraglutide in cardiovascular conditions
Jan, 2037

(12 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions
Jul, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017
New Patient Population(NPP) Dec 04, 2023

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease

Dosage: SOLUTION

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

63. Sofdra patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11123325 BOTANIX SB Formulation for soft anticholinergic analogs
Jul, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 20, 2029

Drugs and Companies using SOFPIRONIUM BROMIDE ingredient

NCE-1 date: 20 June, 2028

Market Authorisation Date: 18 June, 2024

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: GEL, METERED

More Information on Dosage

SOFDRA family patents

Family Patents

64. Sohonos patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10864194 IPSEN Methods for treating heterotopic ossification
Jun, 2037

(12 years from now)

US11622959 IPSEN Methods for treating heterotopic ossification
Jun, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 16, 2028
Orphan Drug Exclusivity(ODE-439) Aug 16, 2030

Drugs and Companies using PALOVAROTENE ingredient

NCE-1 date: 17 August, 2027

Market Authorisation Date: 16 August, 2023

Treatment: Reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva

Dosage: CAPSULE

More Information on Dosage

SOHONOS family patents

Family Patents

65. Sunlenca patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10071985 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10654827 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2027

Drugs and Companies using LENACAPAVIR SODIUM ingredient

NCE-1 date: 22 December, 2026

Market Authorisation Date: 22 December, 2022

Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection

Dosage: TABLET; SOLUTION

More Information on Dosage

SUNLENCA family patents

Family Patents

66. Sunosi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11998639 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(12 years from now)

US10195151 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(12 years from now)

US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(12 years from now)

US10512609 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2024
Orphan Drug Exclusivity(ODE-254) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)

Dosage: TABLET

How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents

67. Sutab patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143656 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Aug, 2037

(12 years from now)

US11638697 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Aug, 2037

(12 years from now)

US11382864 BRAINTREE LABS Solid oral sulfate salt formulations for cleansing a colon and methods of using same
Aug, 2037

(12 years from now)

US11033498 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Aug, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 10, 2023

Drugs and Companies using MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE ingredient

Market Authorisation Date: 10 November, 2020

Treatment: Gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy

Dosage: TABLET

How can I launch a generic of SUTAB before it's drug patent expiration?
More Information on Dosage

SUTAB family patents

Family Patents

68. Syfovre patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11903994 APELLIS PHARMS Dosing regimens
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 22, 2026
New Chemical Entity Exclusivity(NCE) May 14, 2026

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: 14 May, 2025

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of 15 mg pegcetacoplan monthly or every other month

Dosage: SOLUTION

More Information on Dosage

SYFOVRE family patents

Family Patents

69. Terlivaz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335452 MALLINCKRODT IRELAND Method of treating patients with hepatorenal syndrome type 1
Apr, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 14, 2027
Orphan Drug Exclusivity(ODE-406) Sep 14, 2029

Drugs and Companies using TERLIPRESSIN ACETATE ingredient

NCE-1 date: 14 September, 2026

Market Authorisation Date: 14 September, 2022

Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function

Dosage: POWDER

More Information on Dosage

TERLIVAZ family patents

Family Patents

70. Tirosint-sol patent expiration

TIROSINT-SOL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11096913 IBSA High-stability packaged solutions of T4 thyroid hormone
Feb, 2037

(12 years from now)

US10537538 IBSA High-stability packaged solutions of T4 thyroid hormone
Feb, 2037

(12 years from now)




Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 15 December, 2016

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of TIROSINT-SOL before it's drug patent expiration?
More Information on Dosage

TIROSINT-SOL family patents

Family Patents

71. Tlando patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11559530 VERITY Oral testosterone undecanoate therapy
Nov, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: CAPSULE

More Information on Dosage

TLANDO family patents

Family Patents

72. Trikafta (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11453655 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(13 years from now)

US10793547 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11517564 VERTEX PHARMS INC Methods of treatment for cystic fibrosis
Dec, 2037

(13 years from now)

US11179367 VERTEX PHARMS INC Pharmaceutical compositions for treating cystic fibrosis
Dec, 2037

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 08, 2024
New Chemical Entity Exclusivity(NCE) Oct 21, 2024
New Product(NP) Apr 26, 2026
Orphan Drug Exclusivity(ODE-275) Oct 21, 2026
Orphan Drug Exclusivity(ODE-323) Dec 21, 2027
Orphan Drug Exclusivity(ODE-357) Jun 08, 2028
Orphan Drug Exclusivity(ODE-433) Apr 26, 2030

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

NCE-1 date: 22 October, 2023

Market Authorisation Date: 26 April, 2023

Treatment: Treatment of cystic fibrosis in patients aged 2 to <6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering d...

Dosage: GRANULES; TABLET

More Information on Dosage

TRIKAFTA (COPACKAGED) family patents

Family Patents

73. Tryvio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11174247 IDORSIA Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
Nov, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 22, 2029

Drugs and Companies using APROCITENTAN ingredient

NCE-1 date: 22 March, 2028

Market Authorisation Date: 19 March, 2024

Treatment: Treatment of hypertension in combination with other antihypertensive drugs, including an angiotensin receptor blocker, to lower blood pressure in adult patients who are not adequately controlled on ot...

Dosage: TABLET

More Information on Dosage

TRYVIO family patents

Family Patents

74. Veklury patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695361

(Pediatric)

GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Mar, 2037

(12 years from now)

US11382926

(Pediatric)

GILEAD SCIENCES INC Methods for treating Arenaviridae and Coronaviridae virus infections
Mar, 2037

(12 years from now)

US11007208

(Pediatric)

GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Mar, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-183) Jan 21, 2025
New Patient Population(NPP) Apr 25, 2025
New Chemical Entity Exclusivity(NCE) Oct 22, 2025
M(M-301) Jul 13, 2026
Pediatric Exclusivity(PED) Jan 13, 2027

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: 13 January, 2026

Market Authorisation Date: 22 October, 2020

Treatment: NA

Dosage: POWDER; SOLUTION

More Information on Dosage

VEKLURY family patents

Family Patents

75. Vevye patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10813976 HARROW EYE Ophthalmic compositions comprising ciclosporin
Sep, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 30, 2026

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 30 May, 2023

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

VEVYE family patents

Family Patents

76. Victoza patent expiration

VICTOZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968659 NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jan, 2037

(12 years from now)

US9968659

(Pediatric)

NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jul, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
M(M-115) Apr 06, 2015
M(M-176) Apr 22, 2019
New Indication(I-750) Aug 25, 2020
New Patient Population(NPP) Jun 17, 2022
Pediatric Exclusivity(PED) Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 17 December, 2021

Market Authorisation Date: 25 January, 2010

Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...

Dosage: SOLUTION

How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage

VICTOZA family patents

Family Patents

77. Vitrakvi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10137127 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(12 years from now)